Project Overview - The project is named "Biopharmaceutical Raw Materials and Bio-based Materials Production Line Construction Project" [2] - It is a new construction project located in the Weinan Economic and Technological Development Zone [2] - The total investment for the project is 92.871 million yuan, with an environmental investment of 6.737 million yuan, accounting for 7.25% of the total investment [2] - The project aims to establish 9 production lines with an annual output of 200 tons of biopharmaceutical raw materials and bio-based materials, along with various supporting facilities [2] Company Profile - Shaanxi Huasen Shengbang Technology Co., Ltd. is located in the Pucheng Provincial High-tech Industrial Development Zone in Shaanxi Province [4] - The company focuses on high-end biopharmaceutical technology research and development, product manufacturing, and sales [4] - It produces biopharmaceutical intermediates and raw materials, as well as health food raw materials, and collaborates with several universities and research institutes [4] - The company has established research centers in Xi'an and Pucheng, aiming to overcome technical bottlenecks in the biopharmaceutical field through innovative microbial synthesis methods [4] Product Information - The main products currently promoted by the company include ergotioneine, rhodiola rosea glycosides, resveratrol, and tetrahydropyridine [3] Industry Event - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang [6] - The conference focuses on five key areas: AI + biological manufacturing, green chemistry and new materials, future food, future agriculture, and beauty raw materials [7] - It aims to explore the development trends of the biomanufacturing industry and promote the scaling of products and the transfer of scientific achievements [7]

Group 1 - Shaanxi Biochemical Industry Technology Innovation Platform Co., Ltd. (referred to as "Shaanxi Biochemical") and its parent company Huason Shengbang are making significant advancements in the fields of biopharmaceutical intermediates, raw materials, and health food ingredients [1] - In 2021, a core team of five, led by Chairman Weng Jing and General Manager Li Pumin, initiated a "second entrepreneurship" to tackle "bottleneck" technologies, establishing a complete chain from basic research to industrialization [1] - The projects on resveratrol and rhodiola glycosides have been selected as key new product development projects in Shaanxi Province for 2024, indicating a breakthrough in natural product extraction technology [1] Group 2 - Chang'an Bank's financial support has been crucial for the growth trajectory of Huason Shengbang, with a fixed asset loan of 100 million yuan granted on September 20, 2024, specifically for the construction of a research center and procurement of high-end R&D equipment [1] - Chang'an Bank has developed a comprehensive service system covering nearly 40 products through its "Chang'an V+" microfinance brand, with a balance of 47.1 billion yuan in inclusive micro-enterprise loans and 170,000 loan accounts by the end of 2024 [1] - The case of Huason Shengbang reflects Chang'an Bank's deep logic in serving the private economy, having established a "three-special mechanism" to address the characteristics of sci-tech enterprises, providing not only funding but also value-added services such as industry analysis and policy connection [2]

安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 海国际中心 B 座 17 楼） 1-1-0 证券简称： 峆一药业 证券代码： 430478 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...

证券简称： 峆一药业 证券代码： 430478 安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 1-1-0 海国际中心 B 座 17 楼） 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...